Coastal and waterway decisions depend on understanding what is actually happening in the field”— Joel Chaky BATON ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

India, Feb. 18 -- Indian film actress Pravina Deshpande, who featured in Ready starring Salman Khan and had a long run in TV ...

Jaime Suarez-Londono, MD: Transplant for myeloma is very easy to give. On day 12 they engraft and they go home. Adverse events are not that [severe], and they get this progression-free survival [PFS] ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...